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Abstract
Recent technological advances allow the transfer of genes to the synovial lining of joints. As
well as opening novel opportunities for therapy, these techniques provide valuable new tools
for the study of synovitis and other aspects of the biology of joints in health and disease. This
article reviews briefly the results of experiments in which selected genes have been
transferred to the knee joints of healthy rabbits and rabbits with antigen-induced arthritis.
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factor; TNF = tumor necrosis factor; TNFRa = tumor necrosis factor receptor antagonist; vIL-10, viral interleukin 10; WBC = white blood cell.
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Introduction
One approach to the treatment of intra-articular pathologies
involves the transfer of genes to synovium and their
intrasynovial expression [1]. The development of technolo-
gies with which to do this not only opens new therapeutic
possibilities but also permits the study of selected gene
products within the synovial microenvironment. Here we
review briefly the results obtained from such investigations.
Most of these data have been obtained using the rabbit knee
as a model. This joint has the advantage of being large
enough for efficient intra-articular injection and serial
lavage. Moreover, after euthanasia the various intra-articular
tissues can be dissected and independently studied ex vivo.
We utilize gene delivery to the joint in two complimentary
approaches to the study of joint diseases. In the first,
genes whose products have been associated with arthritis
are introduced into the synovium of a normal joint to
determine whether their gene products can provoke syno-
vitis or other joint disturbances. In the second, the genes
are introduced into inflamed joints to determine whether
their products have anti-inflammatory properties. Antigen-
induced arthritis (aia), using ovalbumin as the inciting
antigen, is often employed for these experiments.
Gene transfer to synovium
Previous research has demonstrated the experimental
utility of two methods for delivering genes to the synovial
lining of joints, ex vivo transfer using a retrovirus and in vivo
delivery using an adenovirus (Table 1) [2–4]. The former
approach has been used in a human clinical trial [5], but is
cumbersome and tedious, and selectively targets type B
synoviocytes. For these reasons, most of the experimental
studies described here have involved in vivo gene delivery
by direct, intra-articular injection of adenoviral vectors. This
method is not only simpler but also transduces types A and
B synoviocytes as well as various leukocyte populations
within the joint. These studies have to be performed care-
fully, because the adenoviruses themselves may provoke an
inflammatory response. However, it is possible to titrate
downwards the amount of adenovirus injected into the jointArthritis Research    Vol 1 No 1 Evans et al
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such that an experimentally useful level of gene expression
is achieved with only minimal inflammation resulting from
the virus itself. The intra-articular expression of transgenes
following adenoviral delivery tends to be high initially, but
then declines to undetectable levels within about 2weeks.
Because of this, and the nature of aia in the rabbit knee,
most experiments have studied the acute inflammatory
reaction occurring during the first week of disease. This
period of time also avoids complications that would arise
from a primary immune response to the vector or the trans-
gene products, most of which are heterologous proteins.
Gene transfer to the normal synovium
Ex vivo transfer of the interleukin-1b b gene
The first experiments of this kind were conducted by ex
vivo transfer of a human interleukin (hIL)-1b complemen-
tary (c)DNA [6]. Because the native molecule is not
secreted efficiently, a leader sequence taken from the
parathyroid hormone was fused to the N-terminus of the
molecule. This molecule proved extraordinarily potent.
Indeed in the first experiment where 107 autologous cells
expressing IL-1b were returned to one knee joint, all the
rabbits died or had to be euthanized.
In subsequent experiments, fewer cells were returned to
the joint. Following intra-articular injection of 106 trans-
duced cells, approximately 200pg hIL-1b could be
lavaged from the joints for up to 2weeks, after which gene
expression abruptly stopped. During this 2-week period,
the rabbits developed fevers, lost weight, and their eryth-
rocyte sedimentation rates rose dramatically. Knee joints
receiving the hIL-1b construct were massively swollen
and contained a voluminous, caseinous synovial fluid.
Synovia were enormously hypertrophic and hyperplastic,
not only invading the adjacent cartilage and bone but also
penetrating the capsule into the adjacent muscle, areas of
which became necrotic. It is also remarkable how all non-
erosive components of these pathologies returned to
normal once transgene expression was lost.
Later studies revealed that the transfer of as few as 105
IL-1b+ cells caused considerable intra-articular pathology
despite the absence of detectable hIL-1b in the lavage fluid.
This observation cautions against drawing strong conclu-
sions concerning the pathophysiological roles of potential
mediators based upon their synovial fluid concentrations.
Previous attempts to define intra-articular responses to
IL-1b had relied upon intra-articular injection or pumps to
deliver recombinant protein [7,8]. In neither case were the
sequelae remotely as dramatic as those observed following
transfer of the IL-1b gene. The greater potency of the
gene transfer approach may not only result from its ability
to deliver IL-1b in a sustained fashion, but also from the
production of an authentically processed protein by syno-
viocytes within the synovial microenvironment.
In vivo gene transfer
A variety of genes have been evaluated by in vivo adeno-
viral delivery (Table 2). Expression of a murine tumor
necrosis factor (TNF) cDNA within the synovium of the
rabbit knee produced moderate inflammatory infiltrates,
which were particularly rich in polymorphonuclear leuko-
cytes (our unpublished data, 1998). The release of glycos-
aminoglycans (GAG) from the articular cartilage was
modestly elevated, while GAG synthesis was strongly
depressed. When expressed in combination with an IL-1b
transgene, TNF caused high levels of apoptosis in the
synovium. This suggests that such a combination may
limit synovitis by inducing cell death.
Growth factor genes are being evaluated for their ability to
protect articular cartilage from degradation, as well as to
enhance the repair of damaged cartilage. As discussed in
[9], these genes may be delivered to synovium or to the car-
tilage itself. Transfer of a human transforming growth factor
(TGF)-b1 gene to synovium provoked a massive hyper-
trophy and fibrosis of not only the injected joint, but also
the soft tissues of the entire leg (our unpublished data,
1998). This proved fatal in several animals. When less virus
was administered, pathology was restricted to the injected
knee and included thickening and fibrosis of the synovium.
This suggests that TGF-b may be a mediator of arthrofibro-
sis. Interestingly, the inflammatory infiltrate that often
follows the intra-articular injection of adenoviral particles
was virtually absent when the TGF-b1 gene was present.
Of particular interest was the formation of intrasynovial
cartilage. Recent data suggest that cells within the
synovium have the potential to differentiate into chondro-
cytes and to form cartilage. Our findings indicate that
TGF-b can trigger this pathway and, in this way, lead to
the human condition synovial osteochondromatosis [10].
Synovial delivery of genes encoding insulin-like growth
factor (IGF)-1 and bone morphogenetic protein (BMP)-2,
Table 1
Ex vivo and in vivo gene transfer to the synovial lining of
rabbits’ knee joints*
In vivo Ex vivo
Level of expression High Low–medium
Duration of expression ~ 2 weeks Up to 6 weeks
Transduced cells Types A+B synoviocytes Type B synoviocytes
Various leukocytes
Laboriousness Low High
Inflammatory response Present Absent
*This comparison is based upon ex vivo gene transfer using Moloney-
based retrovirus, and in vivo gene transfer using first generation
adenovirus.23
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in contrast to the TGFb gene, produced a modest eleva-
tion in cartilage GAG synthesis in the absence of major
synovial changes (our unpublished data, 1998).
Nitric oxide (NO) is a radical with a physiological half-life
of several seconds. Although there is literature to suggest
an important role for this molecule in inflammation and
joint disease [11], experimental studies have been ham-
pered by various practical limitations. Among them is the
near impossibility of administering NO to experimental
animals in a pharmacologically useful manner. Transfer of
genes encoding NO synthase solves this problem, and
serves as a particularly good example of the value of the
gene delivery approach to studying disease.
Intrasynovial expression of a cDNA encoding human,
inducible NO synthase (iNOS or NOS-2), produced
remarkably few intra-articular changes beyond a mild influx
of leukocytes into the synovium and the joint space. This
infiltrate was unusual in containing predominantly mono-
cytes and macrophages. The relative absence of neutrophils
may reflect the ability of NO to inhibit the expression of
neutrophil-specific adhesion molecules on the endothelial
lining of the synovial vasculature [12]. The synovium was
slightly thickened, and there was evidence of considerable
neo-vascularization. No effects were seen on the turnover
of cartilage proteoglycans (our unpublished data, 1998).
Gene transfer to the inflamed synovium
Ex vivo transfer of the interleukin-1 receptor antagonist
(IL-1Ra)
Delivery of a cDNA encoding human IL-1Ra one day
after induction of aia had no effect on synovitis, although
it reduced the influx of leukocytes into the joint space and
strongly protected the articular cartilage. For unknown
reasons transgene expression was higher in joints with aia
than in normal joints [13]. Although synovitis was unaf-
fected in this rabbit model, ex vivo transfer of human IL-
1Ra genes did suppress synovitis in streptococcal cell wall
arthritis in rats [14] and collagen-induced arthritis in mice
[15].  Ex vivo delivery of the IL-1Ra gene to joints is
presently the subject of a human clinical trial [5].
In vivo gene transfer
Adenoviral vectors have been used to transfer a number of
additional potentially anti-inflammatory genes to the
synovia of rabbits with aia (Table 3). A gene encoding
bivalent IL-1 soluble type I receptor inhibited the influx
of leukocytes into the joint space and protected the articu-
lar cartilage. Synovitis was moderately reduced [16].
Delivery of a gene encoding bivalent TNF soluble type I
receptor had very little effect beyond a mild reduction in
the inflammatory infiltrate into the joint space. Remark-
ably, a combination of both IL-1 and TNF soluble recep-
tor genes not only protected cartilage and reduced the
leukocytic influx into the joint space, but also inhibited
joint swelling and strongly reduced the synovitis [16].
The viral (v)IL-10 gene was even more potent than the
combination of IL-1 and TNF soluble receptors. Alone, it
strongly reduced swelling, synovitis and leukocytic
infiltration while protecting the articular cartilage [17]. A
similar effect has been noted in the paws of mice with col-
lagen-induced arthritis [18].
In vivo delivery of human Fas ligand (FasL) was associa-
ted with large regions of cellular apoptosis within the
Table 2
Intra-articular effects of various genes following direct delivery
to the synovial lining of normal rabbits knees
Effect*
Cartilage
Gene Edema Synovitis synthesis Breakdown
TNF + ++ – – ++
TGF-b1
† +++ + ± ++
IGF-1 0 0 ++ 0
BMP-2 0 0 ++ 0
iNOS‡ 0+ 00
*Effects are graded on a scale from 0 = no effect to +++ = large
stimulatory effect to – – – = large inhibitory effect. †Delivery of the
TGF-b1 gene was associated with the intrasynovial formation of
cartilage. ‡Delivery of the iNOS gene was associated with
neovascularization of synovium. TNF, tumor necrosis factor; TGF,
transforming growth factor; IGF, insulin-like growth factor; BMP, bone
morphogenetic protein; iNOS, inducible nitric oxide synthase.
Table 3
Intra-articular effects of various genes following direct delivery
to the synovial lining of rabbit knees with antigen-induced
arthritis
Effect*
Cartilage
Gene Edema Synovitis WBC Synthesis Degn
IL-1Ra 0 0/– – NT –
TNFRa 0 0 0/– NT 0
IL-1Ra + TNFRa – – – NT –
vIL-10 – – – + –
IGF-1 0 0 0 + 0
*0, No effect; –, inhibition; +, stimulation; NT, not tested; WBC, white
blood cell infiltrate into the synovial fluid; Degn, degradation; IL-1Ra,
interleukin-1 receptor antagonist; TNFRa, tumor necrosis factor
receptor antagonist; vIL-10, viral interleukin-10; IGF, insulin-like growth
factor.synovium. It is not yet clear whether the level of cell
killing observed under these circumstances is sufficient to
produce a significant anti-arthritic effect in this model (our
unpublished data, 1998). Adenoviral delivery of the FasL
gene does, however, ameliorate disease in murine colla-
gen-induced arthritis [19].
The IGF-1 gene had no effect on synovitis or other
inflammatory components of aia, but was able to increase
the synthesis of GAG by cartilage without influencing
breakdown. Expression of an iNOS gene within the joints
of rabbits with aia had no effect on synovitis or other intra-
articular pathology (our unpublished data, 1998).
The contralateral effect
While performing these experiments, Ghivizzani et al [16]
made an unexpected observation: injection of adenovirus
carrying the soluble IL-1 receptor into one knee joint of
animals with bilateral aia ameliorated disease not only in
the injected knee but also in the contralateral knees
which had received only saline or a marker gene. When a
soluble TNF receptor gene was co-administered, this
‘contralateral effect’ was even stronger. The contralateral
effect was particularly powerful when using the vIL-10
gene [17]. A similar effect occurs in murine collagen-
induced arthritis [18], and several other groups have
reported similar findings suggesting that this is not some
peculiarity of rabbit a.i.a [20].
The mechanism of the contralateral effect may reside
with the ability of leukocytes to traffic between joints.
Following injection of adenoviruses carrying marker
genes into one knee joint of animals with bilateral
disease, it is possible to recover cells expressing those
marker genes from the contralateral knee joints and
draining lymph nodes but not from other organs or the
peripheral blood [16,17]. The identification of these cells
and their possible role as mediators of the contralateral
effect are under investigation.
Conclusions
The ability to transfer genes to the synovium and other
tissues of interest offers unique opportunities for studying
the biology of joints in health and disease. The data
obtained by these means will aid the development of
novel therapeutic approaches, irrespective of their direct
application to gene therapy.
References
1. Evans CH, Ghivizzani SC, Kang R, et al: Gene therapy for rheumatic
diseases. Arthritis Rheum 1999, 42:1–15.
2. Bandara G, Robbins PD, Georgescu HI, Mueller GM, Glorioso JC,
Evans CH: Gene transfer to synoviocytes: prospects for gene
treatment for arthritis. DNA Cell Biol 1992, 11:227–231.
3. Roessler BJ, Allen ED, Wilson JM, Hartman JW, Davidson BL: Aden-
oviral-mediated gene transfer to rabbit synovium in vivo. J Clin
Invest 1993, 92:1085–1092.
4. Nita I, Ghivizzani SC, Galea-Lauri J, et al: Direct gene delivery to syn-
ovium: an evaluation of potential vectors in vitro and in vivo. Arthri-
tis Rheum 1996, 39:820–828.
5. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R: Clinical
trial to assess the safety, feasibility and efficacy of transferring a
potentially anti-arthritic cytokine gene to human joints with
rheumatoid arthritis. Hum Gene Ther 1996, 7:1261–1280.
6. Ghivizzani SC, Kang R, Georgescu HI, et al: Constitutive intraarticu-
lar expression of human IL-1b b following gene transfer to rabbit
synovium produces all major pathologies of human rheumatoid
arthritis. J Immunol 1997, 159:3604–3612.
7. Pettipher ER, Higgs GA, Henderson B: Interleukin-1 induces leuko-
cyte infiltration and cartilage proteoglycan degradation in the syn-
ovial fluid. Proc Natl Acad Sci U S A 1986, 83:8749–8753.
8. Feige U, Karbowski C, Rordorf-Adam C, Pataki A: Arthritis induced
by continuous infusion of hr-interleukin-1a a into the rabbit knee
joint. Int J Tissue React 1989, 11:225–238.
9. Evans CH, Robbins PD: Potential treatment of osteoarthritis by
gene therapy. In: Rheumatic Disease Clinics of North America. Edited
by Brandt K. Philadelphia: WB Saunders Co, 1999, 25:333–344.
10. Milgram JW: Synovial osteochondromatosis: a histopathological
study of thirty cases. J Bone Joint Surg 1977, 59A:792–801.
11. Stefanovic-Racic M, Stadler J, Evans CH: Nitric oxide and arthritis.
Arthritis Rheum 1993, 36:1036–1044.
12. Niu XF, Ibbotson G, Kubes P: A balance between nitric oxide and
oxidants regulates mast cell-dependent neutrophil-endothelial
cell interactions. Circ Res 1996, 79:992–999.
13. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH:
Suppression of antigen-induced arthritis by gene therapy.
J Immunol 1996, 156:3558–3562.
14. Makarov SS, lsen JC, Johnston WN, et al: Suppression of experi-
mental arthritis by gene transfer of interleukin-1 receptor antago-
nist cDNA. Proc Natl Acad Sci U S A 1996, 93:402–406.
15. Bakker AC, Joosten LAB, Arntz OJ, et al: Prevention of murine colla-
gen-induced arthritis in the knee and ipsilateral paw by local
expression of human interleukin-1 receptor antagonist protein in
the knee. Arthritis Rheum 1997, 40:893–900.
16. Ghivizzani SC, Lechman ER, Kang R, et al: Direct adenoviral-medi-
ated transfer of IL-1 and TNF-a a soluble receptors to rabbit knees
with experimental arthritis has local and distal anti-arthritic
effects. Proc Natl Acad Sci U S A 1998, 95:4613–4618.
17. Lechman ER, Jaffurs D, Ghivizzani SC, et al: Direct adenoviral gene
transfer of vIL-10 to rabbit knees with experimental arthritis ame-
liorates disease in both injected and contralateral knees. J Immunol
1999, in press.
18. Whalen JD, Lechman ER, Carlos CA, et al: Adenoviral transfer of the
viral IL-10 gene periarticularly to mouse paws suppresses devel-
opment of collagen-induced arthritis in both injected and unin-
jected paws. J Immunol 1999, 162:3625–3632.
19. Zhang H, Yang Y, Horton JL, et al: Amelioration of collagen-induced
arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest
1997, 100:195–1957.
20. Evans CH, Rediske JJ, Abramson SB, Robbins PD: Joint efforts: tack-
ling arthritis using gene therapy. Mol Med Today 1999, 5:148–151.
Author addresses: Christopher H Evans (Orthopaedic Surgery and
Molecular Genetics & Biochemistry, University of Pittsburgh School of
Medicine, Pittsburgh, Pennsylvania, USA), Steven C Ghivizzani, Eric R
Lechman, Zhebao Mi, Daniel Jaffurs and Paul D Robbins (Molecular
Genetics & Biochemistry, University of Pittsburgh School of Medicine,
Pittsburgh, Pennsylvania, USA)
Correspondence: C H Evans, PhD, DSc, University of Pittsburgh
School of Medicine, Department of Orthopaedic Surgery, 200 Lothrop
Street, Room C313 PUH, Pittsburgh, PA 15213, USA.
Tel: +1 412 648 1092; fax: +1 412 648 8412;
e-mail: cevans@vms.cis.pitt.edu
Arthritis Research    Vol 1 No 1 Evans et al
24